Beurs.nl monitor iconMarkt Monitor
  • AEX 0,00 919,26 0,00%
  • DE40 -288,91 22.999,15 -1,24%
  • US500^ 0,00 5.664,36 0,00%
  • US30^ 0,00 41.975,60 0,00%
  • EUR/USD 0,00 1,0836 -0,20%
  • WTI 0,00 68,33 0,00%
  • Gold spot -12,87 3.033,05 -0,42%

Vivoryon is de naam. Daarom nieuw draadje

6.265 Posts
Pagina: «« 1 ... 107 108 109 110 111 ... 314 »» | Laatste | Omlaag ↓
  1. Muisje 30 augustus 2020 18:10
    quote:

    DeZwarteRidder schreef op 30 augustus 2020 09:21:

    [...]
    Het is slechts een kwestie van tijd.
    Hahaha wat een comedy..
  2. Amarillo 31 augustus 2020 09:55
    Ff wat serieus nieuws van de concurrentie mensen: Neuralink van Elon Musk heeft een chip geimplanterrd in het brein van een varken om zo hersenaandoeningen te kunnen bestrijden waaronder ook Altzheimer..zit ook hier in de testfase en nog bij een varken..oke,oke..maar die moeten we ook ff niet uitvlakken vind in
  3. forum rang 5 K. Wiebes 31 augustus 2020 14:39
    Reactie van Gretchen (dat rood moet je er zelf maar even bij verzinnen):

    Dear K. Wiebes,

    Please see below a transcript of your questions from our call on Friday and the replies
    in dark red from Vivoryon. Please contact me with any further questions.

    “Being that dissenting shareholders would receive €9.00 for their shares, wouldn’t a
    large proportion of shareholders prefer that option since the shares are trading
    significantly below €9?”

    --If shareholders holding more than 2% of the voting rights in the aggregate have an
    objection recorded in the shareholders’ meeting, the conversion and thus the
    compensation offer will not be implemented.
    Therefore, if too many shareholders try to use this proposal as an exit option, no
    compensation will be paid.

    “For example, MorphoSys has sold some of their position and they still own 10%
    of the shares, therefore they would welcome the chance to liquidate their shares
    for the €9.”

    --Again, if they would dissent at such a level (i.e. more than 2%), there is no way
    the transaction goes through and thus, no compensation would be paid.
    Therefore, the compensation offer does not present an exit option, in particular
    not for major shareholders.

    “Is the management therefore convinced that MorphoSys would not dissent
    to the transaction?”

    -- No major shareholder has agreed to the transaction in advance. However,
    given the advantages for the company and its shareholders of the proposed
    N.V. structure, the management believes that all major shareholders will vote
    in favour of the proposed resolution. The legal form of an N.V. would reduce
    administrative efforts for both the Company and its shareholders, would
    facilitate the access to a broader investor base including in the U.S.

    “Since the company requested a valuation analysis to come to the € 8.87 fair
    value of the shares, can Vivoryon please post that analysis report on the website?”

    -- The valuation report is part of the conversion report and will be published
    together with the invitation and the other documents relating to the General
    Meeting on or around 3 September 2020.

    Best regards,
    Gretchen

    Gretchen L.P. Schweitzer
    Managing Director
    Trophic | Communications GmbH

    Nog even een vraag teruggestuurd:
    Het voorstel moet dus met 98% van de stemmen worden aangenomen?
  4. forum rang 10 DeZwarteRidder 31 augustus 2020 14:42
    quote:

    K. Wiebes schreef op 31 augustus 2020 14:39:

    Reactie van Gretchen (dat rood moet je er zelf maar even bij verzinnen):

    Dear K. Wiebes,

    Please see below a transcript of your questions from our call on Friday and the replies in dark red from
    Vivoryon. Please contact me with any further questions.

    “Being that dissenting shareholders would receive €9.00 for their shares, wouldn’t a large proportion of
    shareholders prefer that option since the shares are trading significantly below €9?”

    --If shareholders holding more than 2% of the voting rights in the aggregate have an objection recorded
    in the shareholders’ meeting, the conversion and thus the compensation offer will not be implemented.
    Therefore, if too many shareholders try to use this proposal as an exit option, no compensation will be
    paid.

    “For example, MorphoSys has sold some of their position and they still own 10% of the shares, therefore
    they would welcome the chance to liquidate their shares for the €9.”

    --Again, if they would dissent at such a level (i.e. more than 2%), there is no way the transaction goes
    through and thus, no compensation would be paid. Therefore, the compensation offer does not present
    an exit option, in particular not for major shareholders.

    “Is the management therefore convinced that MorphoSys would not dissent to the transaction?”

    -- No major shareholder has agreed to the transaction in advance. However, given the advantages
    for the company and its shareholders of the proposed N.V. structure, the management believes that
    all major shareholders will vote in favour of the proposed resolution. The legal form of an N.V. would
    reduce administrative efforts for both the Company and its shareholders, would facilitate the access
    to a broader investor base including in the U.S.

    “Since the company requested a valuation analysis to come to the € 8.87 fair value of the shares,
    can Vivoryon please post that analysis report on the website?”

    -- The valuation report is part of the conversion report and will be published together with the
    invitation and the other documents relating to the General Meeting on or around 3 September
    2020.
    Best regards,
    Gretchen
    Gretchen L.P. Schweitzer
    Managing Director
    Trophic | Communications GmbH
    Nog even een vraag teruggestuurd:
    Het voorstel moet dus met 98% van de stemmen worden aangenomen?
    Weet je het nou nog niet.....????
  5. forum rang 5 K. Wiebes 1 september 2020 14:17
    Dear K. Wiebes,

    Please see the answers from Vivoryon to your questions below in red.

    - So the proposal will need 98% of the votes?
    As per German law, to be ratified the proposal will need a majority of 75% of
    the votes cast at the AGM, however, the proposal will not be implemented if
    for more than 2% in total of the overall voting rights (i.e. more than 399,509
    shares) objections are recorded in the minutes of the meeting.

    - And if not: how much money is Viv. willing to spend on compensation?
    The maximum compensation would correspond to a maximum of 2% of the
    shares (out of 19,975,482) at a compensation amount of EUR 9 per share.
    Details will be published on September 3rd on the company’s webpage.

    Should there be additional questions, please let me know.

    Best,
    Gretchen
  6. forum rang 10 DeZwarteRidder 3 september 2020 16:10
    quote:

    @ out of the blue schreef op 3 september 2020 16:06:

    En weg is de mooie stijging. Wat gebeurde daar?
    Dumpie, dumpie natuurlijk.

    Eerst de koers wat omhoogduwen en dan dumpen.
  7. Muisje 3 september 2020 16:15
    Sommige hier zitten echt te wachten tot ze de boel weer naar beneden kunnen .. lachwekkend gewoon!
  8. forum rang 10 DeZwarteRidder 3 september 2020 17:14
    quote:

    Muisje schreef op 3 september 2020 16:15:

    Sommige hier zitten echt te wachten tot ze de boel weer naar beneden kunnen .. lachwekkend gewoon!
    Pas maar op.....!!!
  9. Kuiken 3 september 2020 19:02
    VIVO heeft onderneming laten waarderen door een Zwitsers bedrijf Venture Valuation( oa gefinancierd door Novartis en European Investment Bank) Het bedrijf is actief in de bio/pharma hoek.
    Het rapport doorgelezen en conclusie:

    Ze zien een beperkte kans van slagen van VIVO. Percentages tussen de 2,7 en 11% voor de twee hoofd pipeline-producten.
    Kans van slagen neemt toe naarmate Phase II overgaat naar III en naar approval.
    Tijdstip van implementatie 2027/2029, maar mochten er traject-versnellingen worden afgegeven
    vanwege gunstige onderzoeksresultaten, kan dat ook eerde worden.
    Het is zeker geen Hosanna-rapport Onderzoekers zien veel beren op de weg.
    Maar na vergelijking met vele gelijksoortige ondernemingen en ook het afwegen van de concurrentie, geven ze VIVO TWEE,
    keer de waarde mee van wat er nu op de koersborden staat.

    beetje doorklikken op VIVO-site en u kunt het zelf lezen.
  10. [verwijderd] 4 september 2020 15:50
    quote:

    DeZwarteRidder schreef op 3 september 2020 16:10:

    [...]
    Dumpie, dumpie natuurlijk.

    Eerst de koers wat omhoogduwen en dan dumpen.
    Hoest met je Galapagos?
6.265 Posts
Pagina: «« 1 ... 107 108 109 110 111 ... 314 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.104
AB InBev 2 5.531
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.047
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.825
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.797
Aedifica 3 925
Aegon 3.258 323.033
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.901
Agfa-Gevaert 14 2.062
Ahold 3.538 74.348
Air France - KLM 1.025 35.260
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.153
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.722
AMG 971 134.211
AMS 3 73
Amsterdam Commodities 305 6.743
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 494
Antonov 22.632 153.605
Aperam 92 15.044
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.798
Arcelor Mittal 2.034 320.932
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.586
ASML 1.766 109.762
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.825
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.442